The stock price of NeuroOne Medical Technologies Corp (NASDAQ: NMTC) has dropped by -9.71 compared to previous close of 0.87. Despite this, the company has seen a fall of -13.70% in its stock price over the last five trading days. accesswire.com reported 2024-11-13 that EDEN PRAIRIE, MN / ACCESSWIRE / November 13, 2024 / NeuroOne Medical Technologies Corporation (Nasdaq:NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that it will be participating in the Virtual Investor Summit Microcap Event. The company will be available for 1-on-1 meetings throughout the day in addition to their presentation.
Is It Worth Investing in NeuroOne Medical Technologies Corp (NASDAQ: NMTC) Right Now?
The 36-month beta value for NMTC is also noteworthy at 0.76. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for NMTC is 26.97M, and at present, short sellers hold a 0.46% of that float. The average trading volume of NMTC on November 15, 2024 was 64.40K shares.
NMTC’s Market Performance
NMTC stock saw a decrease of -13.70% in the past week, with a monthly decline of -16.11% and a quarterly a decrease of 6.99%. The volatility ratio for the week is 8.87%, and the volatility levels for the last 30 days are 7.85% for NeuroOne Medical Technologies Corp (NMTC). The simple moving average for the past 20 days is -15.53% for NMTC’s stock, with a -21.12% simple moving average for the past 200 days.
Analysts’ Opinion of NMTC
Many brokerage firms have already submitted their reports for NMTC stocks, with Craig Hallum repeating the rating for NMTC by listing it as a “Hold.” The predicted price for NMTC in the upcoming period, according to Craig Hallum is $2 based on the research report published on March 29, 2022 of the previous year 2022.
NMTC Trading at -15.31% from the 50-Day Moving Average
After a stumble in the market that brought NMTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -60.95% of loss for the given period.
Volatility was left at 7.85%, however, over the last 30 days, the volatility rate increased by 8.87%, as shares sank -16.02% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +1.43% upper at present.
During the last 5 trading sessions, NMTC fell by -13.70%, which changed the moving average for the period of 200-days by -37.52% in comparison to the 20-day moving average, which settled at $0.9245. In addition, NeuroOne Medical Technologies Corp saw -50.57% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NMTC starting from Christianson Mark, who sale 2,189 shares at the price of $0.88 back on Jun 06 ’24. After this action, Christianson Mark now owns 295,035 shares of NeuroOne Medical Technologies Corp, valued at $1,918 using the latest closing price.
Christianson Mark, the Business Development Director of NeuroOne Medical Technologies Corp, sale 25,800 shares at $0.88 during a trade that took place back on Jun 05 ’24, which means that Christianson Mark is holding 297,224 shares at $22,663 based on the most recent closing price.
Stock Fundamentals for NMTC
Current profitability levels for the company are sitting at:
- -3.12 for the present operating margin
- 0.29 for the gross margin
The net margin for NeuroOne Medical Technologies Corp stands at -3.09. The total capital return value is set at -3.8. Equity return is now at value -349.13, with -226.84 for asset returns.
Currently, EBITDA for the company is -11.76 million with net debt to EBITDA at 0.11. When we switch over and look at the enterprise to sales, we see a ratio of 5.8. The receivables turnover for the company is 9.55for trailing twelve months and the total asset turnover is 0.8. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.42.
Conclusion
In summary, NeuroOne Medical Technologies Corp (NMTC) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
